Literature DB >> 32256136

Nomogram for the Individualized Prediction of Survival Among Patients with H7N9 Infection.

Qinglin Cheng1,2, Zhou Sun1, Gang Zhao1, Li Xie1.   

Abstract

BACKGROUND: Until recently, almost all of these studies have identified multiple risk factors but did not offer practical instruments for routine use in predicting individualized survival in human H7N9 infection cases. The objective of this study is to create a practical instrument for use in predicting an individualized survival probability of H7N9 patients.
METHODS: A matched case-control study (1:2 ratios) was performed in Zhejiang Province between 2013 and 2019. We reviewed specific factors and outcomes regarding patients with H7N9 virus infection (VI) to determine relationships and developed a nomogram to calculate individualized survival probability. This tool was used to predict each individual patient's probability of survival based on results obtained from the multivariable Cox proportional hazard regression analysis.
RESULTS: We examined 227 patients with H7N9 VI enrolled in our study. Stepwise selection was applied to the data, which resulted in a final model with 8 independent predictors [including initial PaO2/FiO2 ratio ≤300 mmHg, age ≥60 years, chronic diseases, poor hand hygiene, time from illness onset to the first medical visit, incubation period ≤5 days, peak C-reactive protein ≥120 mg/L], and initial bilateral lung infection. The concordance index of this nomogram was 0.802 [95% confidence interval (CI): 0.694-0.901] and 0.793 (95% CI: 0.611-0.952) for the training and validation sets, respectively, which indicates adequate discriminatory power. The calibration curves for the survival showed optimal agreement between nomogram prediction and actual observation in the training and validation sets, respectively.
CONCLUSION: We established and validated a novel nomogram that can accurately predict the survival probability of patients with H7N9 VI. This nomogram can serve an important role in counseling patients with H7N9 VI and guide treatment decisions.
© 2020 Cheng et al.

Entities:  

Keywords:  H7N9; avian influenza virus; nomogram; predictors; survival

Year:  2020        PMID: 32256136      PMCID: PMC7094003          DOI: 10.2147/RMHP.S242168

Source DB:  PubMed          Journal:  Risk Manag Healthc Policy        ISSN: 1179-1594


  29 in total

1.  Expert Elicitation Provides a Rapid Alternative to Formal Case-Control Study of an H7N9 Avian Influenza Outbreak in the United States.

Authors:  L Gustafson; R Jones; L Dufour-Zavala; E Jensen; C Malinak; S McCarter; K Opengart; J Quinn; T Slater; A Delgado; M Talbert; L Garber; M Remmenga; M Smeltzer
Journal:  Avian Dis       Date:  2018-06       Impact factor: 1.577

2.  Multivariate survival analysis using Cox's regression model.

Authors:  E Christensen
Journal:  Hepatology       Date:  1987 Nov-Dec       Impact factor: 17.425

3.  Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis.

Authors:  Dario Callegaro; Rosalba Miceli; Sylvie Bonvalot; Peter Ferguson; Dirk C Strauss; Antonin Levy; Anthony Griffin; Andrew J Hayes; Silvia Stacchiotti; Cecile Le Pechoux; Myles J Smith; Marco Fiore; Angelo P Dei Tos; Henry G Smith; Luigi Mariani; Jay S Wunder; Raphael E Pollock; Paolo G Casali; Alessandro Gronchi
Journal:  Lancet Oncol       Date:  2016-04-05       Impact factor: 41.316

4.  External validity of the "all-comers" design: insights from the BIOSCIENCE trial.

Authors:  Anna Franzone; Dik Heg; Lorenz Räber; Marco Valgimigli; Raffaele Piccolo; Thomas Zanchin; Kyohei Yamaji; Stefan Stortecky; Stefan Blöchlinger; Lukas Hunziker; Fabien Praz; Peter Jüni; Stephan Windecker; Thomas Pilgrim
Journal:  Clin Res Cardiol       Date:  2016-04-01       Impact factor: 5.460

5.  Changing risk awareness and personal protection measures for low to high pathogenic avian influenza in live-poultry markets in Taiwan, 2007 to 2012.

Authors:  Ming-Der Liu; Ta-Chien Chan; Cho-Hua Wan; Hsiu-Ping Lin; Tsung-Hua Tung; Fu-Chang Hu; Chwan-Chuen King
Journal:  BMC Infect Dis       Date:  2015-06-24       Impact factor: 3.090

6.  Association between Severity of MERS-CoV Infection and Incubation Period.

Authors:  Victor Virlogeux; Minah Park; Joseph T Wu; Benjamin J Cowling
Journal:  Emerg Infect Dis       Date:  2016-03       Impact factor: 6.883

7.  C-Reactive Protein Mediating Immunopathological Lesions: A Potential Treatment Option for Severe Influenza A Diseases.

Authors:  Rongbao Gao; Lijie Wang; Tian Bai; Ye Zhang; Hong Bo; Yuelong Shu
Journal:  EBioMedicine       Date:  2017-07-13       Impact factor: 8.143

8.  Use of Influenza Risk Assessment Tool for Prepandemic Preparedness.

Authors:  Stephen A Burke; Susan C Trock
Journal:  Emerg Infect Dis       Date:  2018-03       Impact factor: 6.883

9.  The Impacts on Health, Society, and Economy of SARS and H7N9 Outbreaks in China: A Case Comparison Study.

Authors:  Wuqi Qiu; Cordia Chu; Ayan Mao; Jing Wu
Journal:  J Environ Public Health       Date:  2018-06-28

10.  Models predicting survival to guide treatment decision-making in newly diagnosed primary non-metastatic prostate cancer: a systematic review.

Authors:  David Thurtle; Sabrina H Rossi; Brendan Berry; Paul Pharoah; Vincent J Gnanapragasam
Journal:  BMJ Open       Date:  2019-06-22       Impact factor: 2.692

View more
  2 in total

1.  A nomogramic model based on clinical and laboratory parameters at admission for predicting the survival of COVID-19 patients.

Authors:  Xiaojun Ma; Huifang Wang; Junwei Huang; Yan Geng; Shuqi Jiang; Qiuping Zhou; Xuan Chen; Hongping Hu; Weifeng Li; Chengbin Zhou; Xinglin Gao; Na Peng; Yiyu Deng
Journal:  BMC Infect Dis       Date:  2020-11-30       Impact factor: 3.090

2.  A dynamic model for individualized prognosis prediction in patients with avian influenza A H7N9.

Authors:  Mingzhi Zhang; Ke Xu; Qigang Dai; Dongfang You; Zhaolei Yu; Changjun Bao; Yang Zhao
Journal:  Ann Transl Med       Date:  2022-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.